SCHEMBL30775231

SCHEMBL30775231

O=C1NCc2cccc(-c3ccccc3)c21

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 8/20 0.61
KDR P35968 7/20 0.61
CA12 O43570 1/20 0.58
CA9 Q16790 1/20 0.58
CLK4 Q9HAZ1 2/20 0.51
DYRK1B Q9Y463 2/20 0.51
TYRO3 Q06418 1/20 0.51
NTRK2 Q16620 1/20 0.51
PARP1 P09874 1/20 0.50
MAP3K9 P80192 2/20 0.49
MAP3K11 Q16584 2/20 0.49
CDK1 P06493 1/20 0.48
PARP10 Q53GL7 1/20 0.47
PARP11 Q9NR21 1/20 0.47
CLK1 P49759 2/20 0.44
CLK2 P49760 2/20 0.44
CLK3 P49761 2/20 0.44
PRCP P42785 1/20 0.44
TDP2 O95551 1/20 0.43
FYN P06241 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14352446 0.86 AURKA (0.58) AURKAKDRCA12CA9CLK4
SCHEMBL14352118 0.78 AURKA (0.52) AURKAKDRCA12CA9PARP1
SCHEMBL5328900 0.76 AURKA (1.00) AURKAKDRCA12CA9PARP1
SCHEMBL28000551 0.74 AURKA (0.75) AURKAKDRCA12CA9DYRK1B
SCHEMBL4818277 0.74 CA12 (1.00) AURKAKDRCA12CA9CLK4
SCHEMBL14896 0.74 CA12 (1.00) AURKAKDRCA12CA9CLK4
SCHEMBL29355184 0.74 CA12 (1.00) AURKAKDRCA12CA9CLK4
SCHEMBL30331758 0.74 PARP10 (0.69) AURKAKDRCA12CA9CLK4
SCHEMBL5329180 0.73 KDR (0.55) AURKAKDRCA12CA9PARP1
Water SCHEMBL19462706 0.72 CA12 (0.95) AURKAKDRCA12CA9CLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US claimed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof EIF2AK4, GCN1, GCGR AURKA 4571/4885KDR 4622/4885CA12 4741/4885
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF EIF2AK4, GCN1, GCGR AURKA 4571/4885KDR 4622/4885CA12 4741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.